0001363213-16-000063.txt : 20160308
0001363213-16-000063.hdr.sgml : 20160308
20160308110853
ACCESSION NUMBER: 0001363213-16-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160304
FILED AS OF DATE: 20160308
DATE AS OF CHANGE: 20160308
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161490697
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2016-03-04
0
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2016-03-04
4
M
0
17594.0
2.49
A
222846
D
Common Stock
2016-03-04
4
S
0
17594.0
10.006
D
205252
D
Common Stock
2016-03-07
4
M
0
2406.0
2.49
A
207658
D
Common Stock
2016-03-07
4
S
0
2406.0
10.0
D
205252
D
Non-Qualified Stock Option (right to buy)
2.49
2016-03-04
4
M
0
17594.0
0.0
D
2016-06-02
Common Stock
17594
521566
D
Non-Qualified Stock Option (right to buy)
2.49
2016-03-07
4
M
0
2406.0
0.0
D
2016-06-02
Common Stock
2406
519160
D
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2014.
Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 29, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
Provided the reporting person remains employed by or acting as a consultant to the Company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10.
/s/Friedhelm Blobel, Ph.D.
2016-03-08